Fujitani B, Maeda J, Tsuboi T, Kadokawa T, Shimizu M
Jpn J Pharmacol. 1983 Oct;33(5):965-70. doi: 10.1254/jjp.33.965.
The effect of gliclazide, a hypoglycemic sulfonylurea, on the formation of prostaglandin (PG) I2 by the aortic rings of normal and streptozotocin-induced diabetic animals was studied. In in vitro experiments, gliclazide (100-300 micrograms/ml) enhanced the spontaneous PGI2 formation by the guinea-pig and rat aorta. Gliclazide also enhanced the transformation of both arachidonic acid and PGH2 to PGI2 in guinea-pig aorta, indicating that one of the main enhancing sites is the step of converting PGH2 to PGI2. In ex vivo experiments, the formation of PGI2 in the aorta of streptozotocin-diabetic rats was markedly reduced as compared with that of normal rats. An oral administration of gliclazide (100-300 mg/kg) significantly restored this reduced formation of PGI2 without any effect on blood glucose level. This enhancing effect of gliclazide may be favorable to the treatment of diabetic microangiopathy.
研究了降糖磺脲类药物格列齐特对正常动物和链脲佐菌素诱导的糖尿病动物主动脉环前列腺素(PG)I2形成的影响。在体外实验中,格列齐特(100 - 300微克/毫升)可增强豚鼠和大鼠主动脉自发形成PGI2的能力。格列齐特还能增强豚鼠主动脉中花生四烯酸和PGH2向PGI2的转化,这表明主要增强部位之一是将PGH2转化为PGI2的步骤。在体内实验中,与正常大鼠相比,链脲佐菌素诱导的糖尿病大鼠主动脉中PGI2的形成明显减少。口服格列齐特(100 - 300毫克/千克)可显著恢复这种降低的PGI2形成,且对血糖水平无任何影响。格列齐特的这种增强作用可能有利于糖尿病微血管病变的治疗。